Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy.

摘要

Menei and colleagues have performed a thorough analysis in their retrospective cohort study from 26 centers in France. They report the overall survival and complication rate associated with the adjuvant use of implantable biodegradable carmustine wafers (Gliadel; MGI Pharma, Bloomington, MN; now Eisai Inc.) for the treatment of primary and recurrent malignant astrocytoma (MA). The authors also investigate the independent association of morbidity and overall survival with combination therapy of temozolomide (TMZ, Stupp protocol) and Gliadel implantation after surgical resection.